Incannex Healthcare Inc. (IXHL)
CIK 1873875 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 12.5M shares as of Sep 24, 2026 (10-K).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool · source filing →
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Series A Warrants | 11.6M | $2.16 | — | — |
| Common Stock Warrants | 2.0M | not tagged | 5y | — |
| First Tranche Warrant | 453,749 | $1.89 | — | — |
| Pre Funded Warrants | 2,715 | $1.0799 | — | — |
| ELOC Warrant | not tagged | $1.66 | — | — |
Tranches exactly as the company dimensioned them in its 10-K filed Sep 25, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 453,749 underlying shares, as reported Mar 13, 2025 (10-Q).
Reported exercise price: $1.89 (aggregate figure as tagged; individual tranches vary).
Balance-sheet fair value of warrants: $3.1M as of Mar 31, 2026.
Rough fully diluted estimate: 13.0M = 12.5M O/S + 453,749 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Convertible Debenture | $10.0M | — | not tagged | — | — |
Notes exactly as the company dimensioned them in its 10-K filed Sep 25, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 12.5M | Sep 24, 2026 |
| + Series A Warrants (if exercised) | 11.6M | Mar 7, 2025 |
| + Common Stock Warrants (if exercised) | 2.0M | Mar 12, 2026 |
| + First Tranche Warrant (if exercised) | 453,749 | Jun 30, 2026 |
| + Pre Funded Warrants (if exercised) | 2,715 | Mar 12, 2026 |
| Fully diluted estimate | 26.6M | +111.8% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 1 executed · 0 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full IXHL workspace
Free to use. No account, no card.